DK0951467T3 - Substituerede nitrogenholdige heterocykliske forbindelser som inhibitorer af p38-proteinkinase - Google Patents
Substituerede nitrogenholdige heterocykliske forbindelser som inhibitorer af p38-proteinkinaseInfo
- Publication number
- DK0951467T3 DK0951467T3 DK97952517T DK97952517T DK0951467T3 DK 0951467 T3 DK0951467 T3 DK 0951467T3 DK 97952517 T DK97952517 T DK 97952517T DK 97952517 T DK97952517 T DK 97952517T DK 0951467 T3 DK0951467 T3 DK 0951467T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitors
- protein kinase
- containing heterocyclic
- heterocyclic compounds
- substituted nitrogen
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- -1 nitrogen-containing heterocyclic compounds Chemical class 0.000 title 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3428896P | 1996-12-18 | 1996-12-18 | |
US08/822,373 US5945418A (en) | 1996-12-18 | 1997-03-20 | Inhibitors of p38 |
US08/862,925 US6147080A (en) | 1996-12-18 | 1997-06-10 | Inhibitors of p38 |
PCT/US1997/023392 WO1998027098A1 (en) | 1996-12-18 | 1997-12-17 | SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0951467T3 true DK0951467T3 (da) | 2003-07-21 |
Family
ID=27364615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97952517T DK0951467T3 (da) | 1996-12-18 | 1997-12-17 | Substituerede nitrogenholdige heterocykliske forbindelser som inhibitorer af p38-proteinkinase |
Country Status (29)
Country | Link |
---|---|
US (1) | US6147080A (xx) |
EP (1) | EP0951467B1 (xx) |
JP (1) | JP4171072B2 (xx) |
CN (2) | CN1284783C (xx) |
AP (1) | AP1136A (xx) |
AT (1) | ATE236165T1 (xx) |
AU (1) | AU738000B2 (xx) |
BG (1) | BG64533B1 (xx) |
BR (1) | BR9714415A (xx) |
CA (1) | CA2274825C (xx) |
CZ (1) | CZ299600B6 (xx) |
DE (1) | DE69720522T2 (xx) |
DK (1) | DK0951467T3 (xx) |
EA (1) | EA002855B1 (xx) |
EE (1) | EE04191B1 (xx) |
ES (1) | ES2202658T3 (xx) |
HK (1) | HK1023340A1 (xx) |
HU (1) | HUP0001125A3 (xx) |
ID (1) | ID21919A (xx) |
IL (1) | IL130349A0 (xx) |
IS (1) | IS5069A (xx) |
NO (1) | NO315047B1 (xx) |
NZ (1) | NZ336146A (xx) |
PL (1) | PL202464B1 (xx) |
PT (1) | PT951467E (xx) |
SK (1) | SK284578B6 (xx) |
TR (1) | TR199902194T2 (xx) |
TW (1) | TW521071B (xx) |
WO (1) | WO1998027098A1 (xx) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091181B2 (en) | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
US6608060B1 (en) * | 1996-12-18 | 2003-08-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
EP1023441A1 (en) | 1997-10-16 | 2000-08-02 | The Board Of Regents, The University Of Texas System | Models and treatments for cardiac hypertrophy in relation with nf-at3 function |
AU1924699A (en) | 1997-12-19 | 1999-07-12 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses |
MY132496A (en) * | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
WO1999061039A2 (en) * | 1998-05-22 | 1999-12-02 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel composition for modulating ischemic cell death |
US6858617B2 (en) | 1998-05-26 | 2005-02-22 | Smithkline Beecham Corporation | Substituted imidazole compounds |
JP2002517486A (ja) | 1998-06-12 | 2002-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | p38のインヒビター |
EP1277740A1 (en) * | 1998-06-12 | 2003-01-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
AU762245B2 (en) * | 1998-09-18 | 2003-06-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
AR023659A1 (es) | 1998-09-18 | 2002-09-04 | Vertex Pharma | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
EP1261334A1 (en) * | 1998-10-20 | 2002-12-04 | Omeros Corporation | Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation |
ES2212657T3 (es) | 1998-11-04 | 2004-07-16 | Smithkline Beecham Corporation | Pirazinas sustituidas piridin-4-il o pirimidin-4-il. |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
JP2002537397A (ja) | 1999-02-22 | 2002-11-05 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症剤としての多環ヘテロ環式誘導体 |
EE04799B1 (et) | 1999-03-12 | 2007-04-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid |
WO2000055152A1 (en) | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
JP2000281588A (ja) * | 1999-03-30 | 2000-10-10 | Sankyo Co Ltd | ガンの予防又は治療薬及びそのスクリーニング方法 |
WO2001001986A1 (en) * | 1999-07-02 | 2001-01-11 | Lipton Stuart A | Method of reducing neuronal injury or apoptosis |
WO2001004115A2 (en) | 1999-07-09 | 2001-01-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
WO2001029042A1 (en) * | 1999-10-21 | 2001-04-26 | F. Hoffmann-La Roche Ag | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
KR100537241B1 (ko) * | 1999-10-21 | 2005-12-19 | 에프. 호프만-라 로슈 아게 | P38 단백질 키나제의 억제제로서의 알킬아미노 치환된이중고리 질소 헤테로고리 화합물 |
US6759410B1 (en) | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
US6982270B1 (en) | 1999-11-23 | 2006-01-03 | Smithkline Beecham Corporation | 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors |
WO2001038314A1 (en) * | 1999-11-23 | 2001-05-31 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
MXPA02009319A (es) * | 2000-03-22 | 2003-03-12 | Vertex Pharma | Inhibidores de p38. |
JP4993838B2 (ja) * | 2000-08-11 | 2012-08-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | P38のインヒビターとしてのピリジン誘導体 |
PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
JP4524072B2 (ja) | 2000-10-23 | 2010-08-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規化合物 |
US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
CA2431904A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
PL366918A1 (en) * | 2001-02-12 | 2005-02-07 | F.Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
GB0112348D0 (en) * | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
GB2375771A (en) * | 2001-05-24 | 2002-11-27 | Univ Leeds | Decellularisation of tissue implant material |
US6552019B1 (en) | 2001-06-11 | 2003-04-22 | John Cochran | Inhibitors of p38 |
US20030066998A1 (en) | 2001-08-02 | 2003-04-10 | Lee Howard Wing Hoon | Quantum dots of Group IV semiconductor materials |
US7005669B1 (en) | 2001-08-02 | 2006-02-28 | Ultradots, Inc. | Quantum dots, nanocomposite materials with quantum dots, devices with quantum dots, and related fabrication methods |
US6710366B1 (en) | 2001-08-02 | 2004-03-23 | Ultradots, Inc. | Nanocomposite materials with engineered properties |
US6794265B2 (en) | 2001-08-02 | 2004-09-21 | Ultradots, Inc. | Methods of forming quantum dots of Group IV semiconductor materials |
US6819845B2 (en) | 2001-08-02 | 2004-11-16 | Ultradots, Inc. | Optical devices with engineered nonlinear nanocomposite materials |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
WO2003060102A2 (en) * | 2002-01-11 | 2003-07-24 | Vertex Pharmaceuticals Incorporated | Crystal structures of jnk-inhibitor complexes and binding pockets thereof |
CA2474239A1 (en) * | 2002-01-18 | 2003-07-24 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
NZ533865A (en) * | 2002-02-12 | 2006-02-24 | Smithkline Beecham Corp | Nicotinamide derivates useful as p38 inhibitors |
WO2003072569A1 (en) | 2002-02-25 | 2003-09-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
US20040034083A1 (en) * | 2002-04-18 | 2004-02-19 | Stephenson Diane T. | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) |
AU2003225072A1 (en) | 2002-04-19 | 2003-11-03 | Smithkline Beecham Corporation | Novel compounds |
ES2318122T3 (es) * | 2002-04-23 | 2009-05-01 | Bristol-Myers Squibb Company | Compuestos de aril cetona pirrolo-triazina utiles como inhibidores de quinasa. |
US7388009B2 (en) * | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
AU2003231034B2 (en) | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
TW200400034A (en) * | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
IL165264A0 (en) * | 2002-05-23 | 2005-12-18 | Cytopia Pty Ltd | Protein kinase inhibitors |
CA2492033A1 (en) | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
CN1980948B (zh) | 2002-11-27 | 2011-08-10 | Dmi生物科学公司 | 治疗由增强磷酸化介导的疾病和病况 |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
ATE482200T1 (de) * | 2003-05-01 | 2010-10-15 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen |
CA2526285A1 (en) | 2003-05-15 | 2004-12-23 | Arqule, Inc. | Inhibitors of p38 and methods of using the same |
PL1635824T3 (pl) * | 2003-06-03 | 2010-01-29 | Novartis Ag | 5-Członowe heterocykliczne inhibitory P-38 |
AU2004259662B2 (en) | 2003-06-26 | 2008-08-07 | Mereo Biopharma 1 Limited | 5-membered heterocycle-based p38 kinase inhibitors |
WO2005007632A1 (en) * | 2003-07-18 | 2005-01-27 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
EP1687284B1 (en) | 2003-07-25 | 2008-10-29 | Novartis AG | p-38 KINASE INHIBITORS |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
US7419978B2 (en) * | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
JP4772690B2 (ja) | 2003-12-03 | 2011-09-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | チューブリン阻害剤 |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
TW200618803A (en) | 2004-08-12 | 2006-06-16 | Bristol Myers Squibb Co | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
WO2006021848A1 (en) * | 2004-08-27 | 2006-03-02 | Ranbaxy Laboratories Limited | Anti-inflammatory agents |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
EP2258704A1 (en) | 2004-10-19 | 2010-12-08 | ArQule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
US7423042B2 (en) | 2005-03-25 | 2008-09-09 | Glaxo Group Limited | Compounds |
TW200724142A (en) | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
SG160438A1 (en) | 2005-03-25 | 2010-04-29 | Glaxo Group Ltd | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5- d]pyrimidin-2(1h)-one derivatives |
AR053346A1 (es) | 2005-03-25 | 2007-05-02 | Glaxo Group Ltd | Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38 |
US20060235020A1 (en) * | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
CN101273039A (zh) * | 2005-08-12 | 2008-09-24 | 默克公司 | 可用作p38激酶抑制剂的杂二环化合物 |
AU2006306991A1 (en) | 2005-10-28 | 2007-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof |
AU2007223342A1 (en) * | 2006-03-07 | 2007-09-13 | Bristol-Myers Squibb Company | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors |
CN101616667A (zh) * | 2006-10-27 | 2009-12-30 | 百时美施贵宝公司 | 可用作激酶抑制剂的杂环酰胺化合物 |
US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
CA2681420A1 (en) * | 2007-03-20 | 2008-09-25 | Cadila Pharmaceuticals Limited | P38 inhibitors |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2111861A1 (en) | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
WO2009155388A1 (en) | 2008-06-20 | 2009-12-23 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
EP2307411B1 (en) * | 2008-06-20 | 2014-01-01 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as kinase inhibitors |
WO2010038428A1 (ja) * | 2008-09-30 | 2010-04-08 | 武田薬品工業株式会社 | タキサン系抗がん剤の置き換え薬 |
MX2011008276A (es) | 2009-02-06 | 2011-12-14 | Elan Pharm Inc | Inhibidores de quinasa jun n-terminal. |
GB0902648D0 (en) | 2009-02-17 | 2009-04-01 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
GB0908317D0 (en) * | 2009-05-14 | 2009-06-24 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
WO2012031057A1 (en) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms- 582949 for the treatment of resistant rheumatic disease |
AU2012253615B2 (en) * | 2011-05-09 | 2017-03-02 | Eip Pharma, Llc | Compositions and methods for treating Alzheimer's disease |
US20150044178A1 (en) | 2011-12-28 | 2015-02-12 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
CN103772392A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
JP6730701B2 (ja) | 2013-11-14 | 2020-07-29 | 学校法人同志社 | 細胞増殖促進または細胞障害抑制による角膜内皮治療薬 |
WO2016007616A1 (en) | 2014-07-09 | 2016-01-14 | Eip Pharma, Llc | Methods for treating neurologic disorders |
ES2908041T3 (es) | 2015-10-27 | 2022-04-27 | Childrens Hospital Med Ct | Uso de inhibidores de MAPK para reducir la pérdida de células madre hematopoyéticas durante el cultivo ex vivo y la manipulación genética |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
US11479770B2 (en) | 2017-10-05 | 2022-10-25 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of DUX4 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
WO2019226213A2 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
EP3889156A4 (en) * | 2018-11-30 | 2022-07-20 | Shanghai Pharmaceuticals Holding Co., Ltd. | HETEROCYCLIC COMPOUND CONTAINING NITROGEN, COMPOSITION BASED THEREOF, METHOD FOR THE PREPARATION AND USE THEREOF |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716972A (en) * | 1993-01-13 | 1998-02-10 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
WO1995021654A1 (en) * | 1994-02-10 | 1995-08-17 | Vladimir Ivanovich Ivanov | Device for phono-electrophoresis |
US5559137A (en) * | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
EP0802908A4 (en) * | 1995-01-12 | 2001-04-11 | Smithkline Beecham Corp | NEW COMPOUNDS |
AU702146B2 (en) * | 1995-10-06 | 1999-02-11 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
AU736316B2 (en) * | 1996-05-20 | 2001-07-26 | Signal Pharmaceuticals, Inc. | Mitogen-activated protein kinase p38-2 and methods of use therefor |
ATE294174T1 (de) * | 1996-06-10 | 2005-05-15 | Merck & Co Inc | Substituierte imidazole mit cytokinin- inhibirender wirkung |
GB9613021D0 (en) * | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
AU3044197A (en) * | 1996-07-11 | 1998-02-09 | Pfizer Inc. | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists |
WO1998006715A1 (en) * | 1996-08-09 | 1998-02-19 | Smithkline Beecham Corporation | Novel piperazine containing compounds |
US5945418A (en) * | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
-
1997
- 1997-06-10 US US08/862,925 patent/US6147080A/en not_active Expired - Lifetime
- 1997-12-17 AU AU56105/98A patent/AU738000B2/en not_active Ceased
- 1997-12-17 CZ CZ0216399A patent/CZ299600B6/cs not_active IP Right Cessation
- 1997-12-17 HU HU0001125A patent/HUP0001125A3/hu unknown
- 1997-12-17 AP APAP/P/1999/001565A patent/AP1136A/en active
- 1997-12-17 IL IL13034997A patent/IL130349A0/xx active IP Right Grant
- 1997-12-17 CN CNB031587968A patent/CN1284783C/zh not_active Expired - Fee Related
- 1997-12-17 SK SK805-99A patent/SK284578B6/sk not_active IP Right Cessation
- 1997-12-17 EE EEP199900252A patent/EE04191B1/xx not_active IP Right Cessation
- 1997-12-17 BR BR9714415-0A patent/BR9714415A/pt active Search and Examination
- 1997-12-17 DK DK97952517T patent/DK0951467T3/da active
- 1997-12-17 TR TR1999/02194T patent/TR199902194T2/xx unknown
- 1997-12-17 JP JP52797598A patent/JP4171072B2/ja not_active Expired - Fee Related
- 1997-12-17 ID IDW990553A patent/ID21919A/id unknown
- 1997-12-17 CA CA002274825A patent/CA2274825C/en not_active Expired - Fee Related
- 1997-12-17 PT PT97952517T patent/PT951467E/pt unknown
- 1997-12-17 CN CNB971813825A patent/CN1153770C/zh not_active Expired - Fee Related
- 1997-12-17 NZ NZ336146A patent/NZ336146A/xx unknown
- 1997-12-17 ES ES97952517T patent/ES2202658T3/es not_active Expired - Lifetime
- 1997-12-17 EP EP97952517A patent/EP0951467B1/en not_active Expired - Lifetime
- 1997-12-17 PL PL334133A patent/PL202464B1/pl not_active IP Right Cessation
- 1997-12-17 WO PCT/US1997/023392 patent/WO1998027098A1/en active Application Filing
- 1997-12-17 EA EA199900559A patent/EA002855B1/ru not_active IP Right Cessation
- 1997-12-17 AT AT97952517T patent/ATE236165T1/de not_active IP Right Cessation
- 1997-12-17 DE DE69720522T patent/DE69720522T2/de not_active Expired - Fee Related
- 1997-12-18 TW TW086119152A patent/TW521071B/zh not_active IP Right Cessation
-
1999
- 1999-06-07 IS IS5069A patent/IS5069A/is unknown
- 1999-06-17 NO NO19992960A patent/NO315047B1/no not_active IP Right Cessation
- 1999-07-13 BG BG103575A patent/BG64533B1/bg unknown
-
2000
- 2000-04-18 HK HK00102323A patent/HK1023340A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0951467T3 (da) | Substituerede nitrogenholdige heterocykliske forbindelser som inhibitorer af p38-proteinkinase | |
DK0912559T3 (da) | Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer | |
DK1077943T3 (da) | Heterocykliske inhibitorer af p38 | |
NO20021781D0 (no) | Heteroalkylamino-substituerte bicykliske nitrogenheterocykler som inhibitorer for P38-proteinkinase | |
ID22982A (id) | PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38 | |
NO20021783D0 (no) | Alkylamino-substituerte bicykliske nitrogen-heterocykler som inhibitorer for P38-protein-kinase | |
DK1114051T3 (da) | Inhibitorer for p38 | |
NO20012456L (no) | Substituerte pyrazoler som p38 kinase inhibitorer | |
LTPA2014028I1 (lt) | Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai | |
NO990123D0 (no) | Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer | |
NO990124D0 (no) | Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer | |
EE04616B1 (et) | Bitsüklilised heteroaromaatsed ühendid kui valgu türosiini kinaasi inhibiitorid | |
DK0842945T3 (da) | Heterocykliske forbindelser som inhibitorer af leukocytadhæsionen og VLA-4-antagonister | |
DK1117659T3 (da) | Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser | |
FI962800A (fi) | Fenyyliheterosyklisiä yhdisteitä COX-2 inhibiittoreina | |
EE200000289A (et) | Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid | |
DK1353916T3 (da) | Pyrazolforbindelser der er egnede som proteinkinaseinhibitorer | |
DE69716615D1 (de) | Heterozyklische metalloproteaseinhibitoren | |
DK1100797T3 (da) | Heterocycliske forbindelser som inhibitorer af rotamaseenzymer | |
DK1060178T3 (da) | Heterocyklisk forbindelser som inhibitorer af rotamase enzymer | |
DK1317448T3 (da) | Pyrazolforbindelser der er nyttige som proteinkinaseinhibitorer |